Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study

Hao Wang, Lucille J. Russell, Kathleen M. Kelly, Steven Wang and John Thipphawong*

Abstract
Background: This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal antibody directed against nerve growth factor (NGF), for pain relief in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).

Methods: In this multicenter, double-blind study, adults with IC/BPS (i.e., interstitial cystitis symptom index [ICSI] total score ≥8) accompanied by chronic, moderate-to-severe pain were randomized to fulranumab 9 mg or matching placebo, administered subcutaneously at weeks 1, 5, and 9. The primary efficacy endpoint was change from baseline to study endpoint (week 12 or at withdrawal) in average daily pain intensity score. Key secondary endpoints included change from baseline to study endpoint in worst pain intensity score, ICSI total score, Pelvic Pain and Urgency/Frequency total score, Patient Perception of Bladder Condition score, and global response assessment.

Results: This study was terminated prematurely based on concern that this class may be associated with rapidly progressing osteoarthritis or osteonecrosis. Thirty-one patients (of the targeted 70 patients) were randomized, 17 to placebo and 14 to fulranumab, with 15 and 10 patients, respectively, receiving all 3 doses of double-blind treatment. In ANOVA analyses, there was no statistically significant difference between treatment groups for the primary endpoint (LS mean difference [95% CI] vs. placebo, -0.2 [-1.52, 1.10]) or any of the secondary endpoints. Fulranumab was well tolerated, with no patient discontinuing due to an adverse event or experiencing a joint-related serious adverse event over a 26-week follow-up period. No events related to the neurologic or motor systems were reported.

Conclusions: Efficacy was not demonstrated in the present study with the single dose tested and a limited sample size, leading to lack of statistical power. These findings do not exclude the possibility that fulranumab would provide clinical benefit in a larger study and/or specific populations (phenotypes) in this difficult to treat pain condition.

Trial registration: NCT01060254, registered January 29, 2010.

Keywords: Fulranumab, Pain, Analgesia, Interstitial cystitis, Bladder

* Correspondence: JThippha@its.jnj.com
Janssen Research & Development, LLC, Raritan/Titusville, NJ, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Pain (suprapubic related to bladder filling, pelvic, and/or in extragenital locations such as the lower abdomen/back) is the hallmark symptom of interstitial cystitis/bladder pain syndrome (IC/BPS) [1]. Several lines of evidence suggest that IC/BPS can be conceptualized as a bladder pain syndrome associated with not only chronic pain, but also voiding-related symptoms and, in many, other chronic systemic pain disorders. As such, pain management is central to multimodal therapeutic strategies for IC/BPS, given its bearing on psychosocial functioning and quality of life [2, 3]. In fact, recently published IC/BPS guidelines from the American Urological Association recommend pain management as first-line treatment, which should be offered to all patients [1]. Despite the need of IC/BPS patients for analgesia, effective pharmacological treatment for their chronic pain remains elusive [4–6].

In the midst of a growing need for alternative analgesics, nerve growth factor (NGF) antagonism is a focus of drug research and development, with anti-NGF agents in the spotlight [7]. Experimental and clinical evidence has established the major role of NGF in the generation and maintenance of pain states, and specifically in bladder pain in animal models [7–9]. Several humanized and fully human anti-NGF monoclonal antibodies have entered clinical trials as potential analgesics, with preliminary results showing significant improvement in chronic pain from osteoarthritis [10] and diabetic peripheral neuropathy [11, 12] and mixed results for relief of chronic low back pain [13]. Efficacy for interstitial cystitis was also tested initially with positive results [14], but failed to show treatment effect versus placebo in a second study of chronic prostatitis/chronic pelvic pain syndrome [15].

Fulranumab, a fully human recombinant monoclonal antibody (immunoglobulin G), is a potent inhibitor of human NGF. Results from phase 2, randomized, placebo-controlled studies of fulranumab demonstrate a positive dose response in diabetic peripheral neuropathic pain [11], mixed efficacy results versus placebo and statistically significant improvement versus an opioid in pain of osteoarthritis [16, 17], and did not separate from placebo for low-back pain [18]. We herein report the results of a phase 2a study conducted to explore the efficacy and safety profile of fulranumab, as compared to placebo, in patients with moderate-to-severe chronic bladder pain from IC/BPS. On December 23, 2010, the United States Food and Drug Administration (FDA) placed ongoing fulranumab studies on clinical hold because of a concern that the entire class of anti-NGF antibodies may be associated with a condition representing either rapidly progressive osteoarthritis or osteonecrosis [19]. As a result, the sponsor discontinued this study prematurely, after having enrolled only 31 of the targeted 70 patients.

Methods

Ethical practices

An Independent Review Board (US) or Research Ethics Board (Canada) at each study site approved the study protocol and protocol amendments. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written informed consent before study participation. The study is registered at clinicaltrials.gov, NCT 01060254.

Patients

Study participants were adult (≥18 to 80 years, inclusive) men and women with IC/BPS based on a total score ≥8 on the validated O’Leary-Sant interstitial cystitis symptom index (ICSI) [20, 21] and chronic bladder pain for at least 6 months prior to screening, accompanied by urinary urgency, urinary frequency (≥8 voids daily), and/or nocturia. On the basis of patients’ self-assessment of pain using a 11-point numerical rating scale (NRS) (0 = “no pain”, 10 = “worst pain imaginable”), the mean of the average pain intensity scores for the last 7 days of screening had to be ≥5 based on at least 6 of 7 days for eligible patients [22]. Other key eligibility criteria required that patients had no evidence of a urinary tract infection or significant urological disease, including neurogenic bladder and diabetic cystopathy, and had not received intravesical therapy or undergone cystoscopy during the 6 weeks prior to screening. In addition, they had not received opioid analgesic in a dosage of oral morphine equivalent ≥40 mg/day or changed drugs known to affect IC/BPS-associated pain (i.e., antidepressants, antihistamines, antispasmodics, anticholinergics, anticonvulsants) within the 4 weeks before screening.

Study design

This randomized, double-blind, placebo-controlled, multicenter study was conducted between March 2010 and June 2011 (last study visit) at 12 study sites (10 in US and 2 in Canada). Reports of spontaneous reporting of joint replacements were collected through November 2011 (explanation provided under Safety Assessments). The study comprised a screening period of up to 4 weeks, a 12-week double-blind treatment period, and a post-treatment period that concluded 26 weeks after the final dose of study drug was administered.

Eligible patients were randomized in a 1:1 ratio, based on a computer-generated randomization schedule, to fulranumab 9 mg or matching placebo injected subcutaneously (SC) into the thigh (or abdominal wall, only if the thigh was not feasible) once every 4 weeks (i.e., at weeks 1, 5, and 9 visits). Randomization was balanced using randomly permuted blocks and was stratified by...
the presence versus absence of glomerulations and/or Hunner’s ulcer on cystoscopy [23] and by baseline body
weight (<85 kg vs. ≥ 85 kg). Patients were followed during the double-blind treatment period at clinic visits
conducted at baseline and every other week through week 13.

If patients used regularly scheduled bladder pain medi-
cations within 3 months before screening, they could con-
tinue taking them (with no dose changes) concomitantly
with study drug. In addition, rescue use of acetaminophen
(up to 3000 mg/day) was allowed throughout the study.

**Efficacy assessments**

At each study visit, patients received a diary into which they
recorded a bladder pain NRS score for average and
worst pain over the previous 24 h, urinary frequency
daytime and nocturnal), and interference with sleep for
the 7 days before clinic visits. At all clinic visits, patients
rated the degree to which their IC/BPS caused them
problems using the Patient Perception of Bladder Condition
(PPBC) instrument [24] and the number of noctur-
 nal awakenings for voiding, pain with sexual activity,
bladder/pelvic pain, and the frequency of bother with
these symptoms using the Pelvic Pain and Urgency/Fre-
quency Questionnaire (PUF) [25]. At selected clinic
visits (weeks 5, 9, and 13), patients also rated the pres-
ence and extent of their IC/BPS symptoms (urinary ur-
gency, urinary frequency, nocturia, pain/burning in the
bladder) by completing an ICSI questionnaire and their
overall status since beginning study medication by com-
pleting the 7-point global response assessment (GRA):
very much worse; much worse; minimally worse; not
changed; minimally improved; much improved; and very
much improved.

**Safety assessments**

Investigators monitored adverse events throughout the
study. They also performed other standard safety assess-
ments (i.e., clinical laboratory tests, vital signs, physical
examination) at prespecified time points.

An independent data monitoring committee, including
3 medical experts in pain and neurology and 1 statisti-
cian, reviewed unblinded safety data on an ongoing basis
to ensure patient safety. This review did not identify any
safety signal that met prespecified stopping rules.

In response to an FDA request, additional information
to assess patient’s joints was collected to evaluate
whether rapidly progressing osteoarthritis or osteonec-
rosis occurred during the study. The tests included im-
aging data and/or historical data (e.g., X-rays, MRIs,
ultrasounds, historical data pertaining to the joint re-
placement) of any joint that had been replaced or in
which a relevant joint-related adverse event occurred.

The study remained open until November 2011 to ac-
commodate this request.

**Data analysis**

Efficacy analyses were performed on the intent-to-treat
(ITT) data set, namely, all patients who were random-
ized, received at least 1 dose of study drug, and had at
least 1 efficacy evaluation during the double-blind treat-
ment period.

**Efficacy endpoints and analyses**

The primary efficacy endpoint, defined as change in
average pain intensity from the baseline bladder pain in-
tensity score at study endpoint (i.e., end of the double-
blind treatment phase or at the withdrawal visit), was
analyzed using an analysis of variance (ANOVA) model,
which included treatment group as factor. For patients
who terminated before completing 12 weeks of treat-
ment, the last observed data were carried forward to
endpoint for analysis. Analyses of secondary efficacy
endpoints were conducted using a similar ANOVA
model.

**Sample size determination**

In the absence of data on bladder pain effect size in IC/
BPS patients and specific effects of fulranumab, sample
size assumptions for this study were based on those
from another study [16] that was ongoing at the time
the protocol for this study was written. Assuming a
treatment difference of 1.4 in the change from baseline
in average pain intensity score between fulranumab and
placebo, a standard deviation (SD) of 2.4, and an overall
discontinuation rate of 20%, then a sample size of 35 pa-
tients per treatment group or total 70 patients in the en-
tire study would have provided 78.8% power using a
type 1 error rate of 0.1 and a 1-sided 2 sample t-test.

**Results**

**Patients**

A total of 83 patients were screened and 31 eligible pa-
tients were randomized, 17 to placebo and 14 to fulranu-

mab. On December 23, 2010, the FDA placed ongoing
fulranumab studies on clinical hold because of a concern
that the entire class of anti-NGF antibodies may be asso-
ciated with a condition representing either rapidly pro-
gressing osteoarthritis or osteonecrosis [19]. As a result,
the sponsor discontinued this study prematurely, after
having enrolled only 31 of the targeted 70 patients.

Of the 31 randomized patients, 24 completed the
study and 7 were withdrawn from the study prematurely
(Table 1). Two of 17 patients in the placebo group and 4
of 14 patients in the fulranumab group did not receive
all 3 doses of double-blind study drug.
The treatment groups were well-matched based on demographic and most other baseline characteristics (Table 2). The ITT data set was composed primarily of women (83.9%); the mean (SD) age was 48.2 (12.34) years. Patients in the placebo group reported longer IC/BPS disease duration (mean, 9.4 vs. 5.8 years for the fulranumab group) and higher daytime urinary frequency (mean, 16.5 vs. 10.8); mean baseline daily NRS scores for average (6.6 vs. 5.7) and worst (7.6 vs. 6.6) bladder pain scores were similar between the treatment groups, as was the frequency of nocturnal urinary frequency (4.9 vs. 3.7). Of the UPOINT domains, the fulranumab group had a higher percentage of patients in the infection and neurological/systemic domains than the placebo group (Table 2).

Sixteen patients in the placebo group and 12 of 14 (86%) in the fulranumab group received concomitant IC/BPS medications with study drug, the most common being pentosan polysulfate sodium (PPS) (7 patients in each treatment group); a benzodiazepine (6 and 5 patients in the placebo and fulranumab groups, respectively), a corticosteroid (4 and 2 patients in the respective groups), an antidepressant (7 and 3 patients in the respective groups), an antihistamine (5 and 6 patients in the respective groups), an anticholinergic (1 and 3 patients in the respective groups), and an anti-infective agent (3 and 2 patients in the respective groups).

Efficacy results
There was no statistically significant difference between fulranumab and placebo for the primary efficacy endpoint (Table 3). The responder rates based on 30 and 50% improvement at the study endpoint in the average pain intensity score were also similar between the treatment groups (Fig. 1). The responder rate based on 30% improvement in average pain score at study endpoint in the ITT data set was 30.8% for patients treated with fulranumab and 33.3% for placebo patients.

There were no statistically significant between-group differences for any of the secondary endpoints (Table 3), however, there was a trend of better GRA. Five (35.7%) patients in the fulranumab group and 4 (23.5%) patients in the placebo group reported a GRA score of “very much improved” or “much improved”, 5 patients in each group (35.7% and 29.4%, respectively) reported a GRA score of “minimally improved”, and 4 (28.5%) and 8 (47.1%) patients in the respective groups reported “not changed”, “minimally changed”, or “much worse”.

Safety results
The safety profile of fulranumab was similar to that of placebo. The most frequently reported adverse events in the fulranumab group were diarrhea, carpal tunnel syndrome, and urinary tract infection (Table 4). In both treatment groups, most adverse events were mild or moderate in intensity and were reported to be either not related or doubtfully related to the study drug. The only serious adverse event (kidney infection) was reported in the placebo group.

### Table 1 Patient disposition

| Characteristic                          | Placebo (N = 17) | Fulranumab 9 mg (N = 14) |
|----------------------------------------|------------------|--------------------------|
| Randomized                             | 17 (100)         | 14 (100)                 |
| Received all 3 doses of study drug     | 15 (88)          | 10 (71)                  |
| Completed the study                    | 14 (82)          | 10 (71)                  |
| Withdraw from the study                | 3 (18)           | 4 (29)                   |
| Sponsor discontinued the study         | 1 (6)            | 0 (0)                    |
| Patient withdrew consent               | 2 (12)           | 0 (0)                    |
| Other                                  | 0 (0)            | 4 (29)                   |

*Two patients did not meet inclusion/exclusion criteria, 1 patient missed the Week 9 dose, and 1 patient withdrew due to the clinical hold.

### Table 2 Demographic and baseline characteristics (ITT data set)

| Characteristic                          | Placebo (N = 17) | Fulranumab 9 mg (N = 14) |
|----------------------------------------|------------------|--------------------------|
| Sex, n (%)                             |                  |                          |
| Female                                 | 13 (76.5)        | 13 (92.2)                |
| Male                                   | 4 (23.5)         | 1 (7.1)                  |
| Race, n (%)                            |                  |                          |
| White                                  | 16 (94.1)        | 13 (92.9)                |
| Black or African American              | 1 (5.9)          | 1 (7.1)                  |
| Age (years)                            |                  |                          |
| Mean ± SD                              | 46.2 (13.56)     | 50.6 (10.68)             |
| Range                                  | 25–69            | 38–78                    |
| Body weight (kg)                       |                  |                          |
| Mean ± SD                              | 78.9 (16.61)     | 71.7 (26.12)             |
| Range                                  | 54–117           | 46–148                   |
| UPOINT clinical phenotyping, n (%)     |                  |                          |
| Urinary                                | 17 (100)         | 14 (100)                 |
| Psychosocial                           | 5 (29)           | 3 (21)                   |
| Organ-specific                         | 16 (94)          | 11 (79)                  |
| Infection                              | 4 (24)           | 5 (36)                   |
| Neurological/systemic                  | 7 (41)           | 9 (64)                   |
| Tender point                           | 12 (71)          | 9 (64)                   |
| Duration of interstitial cystis (years)|                  |                          |
| Mean ± SD                              | 9.4 (9.87)       | 5.8 (5.44)               |
| Range                                  | 2–40             | 1–20                     |
| Hunner’s ulcer and/or glomerulation, n (%) |        |                          |
| Yes                                    | 9 (52.9)         | 10 (71.4)                |
| No                                     | 8 (47.1)         | 4 (28.6)                 |


No study patient discontinued study drug due to an adverse event.

Regarding adverse events of clinical interest (related to anti-NGF antibodies), none of the study patients had joint-related serious adverse events. No event related to bradycardia, hepatic failure, acute renal failure, or neurologic and motor system was reported. One patient (in the placebo group) experienced a hypotension-related adverse event.

**Discussion**

In this multicenter, double-blind, randomized study of 31 adults with a diagnosis of IC/BPS who suffered from chronic, moderate-to-severe bladder pain, a treatment
effect (vs. placebo) was not observed with fulranumab, based on the primary study endpoint or any of the secondary endpoints. A trend for improvement was observed on the GRA, considering all subcategories, however this finding needs to be confirmed. Patient enrollment was curtailed at an early stage due to a regulatory hold on clinical studies, preventing complete efficacy and safety analysis, reducing power (from 79 to 52%), and limiting conclusions. In addition, an imbalance in the baseline characteristics of the two treatment groups was detected, further diminishing the ability to definitively rule out a potential treatment effect. The development of anti-NGF antibodies was re-initiated in 2015 in patients with osteoarthritis and low back pain (NCT02301234, NCT0252818, NCT02528253, and NCT02683239; at clinical trials.gov). Further development of anti-NGF agents in patients with IC/BPS will be dependent on the safety profile observed in the osteoarthritis and low back pain studies.

The therapy of IC/PBS is usually multimodal and is rarely satisfactory [26–28]. With the exception of PPS (Elmiron), there are currently no approved pharmacologic therapies in the United States for IC/BPS. Many pharmacologic therapies such as antidepressants and antihistamines are used off label. Other therapies include intravesical installation of agents, bladder distention, and surgical intervention [26–28]. Promising agents have been studied, but with mixed results, and none have gained regulatory approval. In this regard, Evans et al. reported significant improvement in pain and the GRA 6 weeks after a single IV infusion of another anti-NGF monoclonal antibody, but no improvement on the ICSI in a pilot study of 64 patients with IC/BPS [14]. The same anti-NGF antibody was tested in a second clinical study of over 200 patients with IC/BPS that was terminated for futility (NCT00999518) [29].

Limitations of this study were early termination of the study resulting in small sample size and some patients not receiving 3 doses of study drug, as well as imbalance between the treatment groups based on baseline characteristics. For example, patients in the placebo group reported longer IC/BPS disease duration (mean, 9.4 vs. 5.8 years for the fulranumab group) and higher daytime urinary frequency (mean, 16.5 vs. 10.8); and of the UPOINT domains, the fulranumab group had a higher percentage of patients in the infection and neurological/systemic domains than the placebo group (Table 2). In addition, due to the heterogeneous population, multiple factors that are impractical to stratify may confound or increase the noise of the study; these include concomitant IC/BPS medication types/rate of usage, and

| Table 4 | Treatment-emergent adverse events reported in ≥10% of patients in either treatment group |
|---|---|---|---|
| Any adverse event | Placebo (N = 17) | Fulranumab 9 mg (N = 14) |
| Diarrhea | 2 (12) | 3 (21) |
| Carpal tunnel syndrome | 0 | 2 (14) |
| Urinary tract infection | 2 (12) | 2 (14) |
| Pain | 2 (12) | 0 |
| Pain in extremity | 2 (12) | 0 |
| Paresthesia | 2 (12) | 0 |
| Sinusitis | 2 (12) | 0 |

Adverse events are presented in decreasing order of incidence for the fulranumab group.
commonly comorbid conditions (e.g., irritable bowel disease, depression, pelvic floor dysfunctional disease) that define different clinical phenotypes [30]. Clinical trials of IC/BPS have been limited, in general, by substantial heterogeneity in methodology, symptoms assessment, duration of treatment, and follow-up [31]. For example, although initial trials were positive for PPS [32, 33], subsequent large confirmatory trials have had mixed results [34]. Experts have recently advanced the use of clinical phenotypes based on UPOINT or pain mapping/pain location in IC/BPS research [30, 35]. With regard to analgesia for IC/BPS, future studies should include mapping of pain sites (i.e., restricted to the pelvis; pain sites beyond the pelvis) and the quality/severity of pain at those sites, assuring differentiation between IC/BPS and other pain syndromes by patients, as well as correlate findings from these assessments with associated comorbid, chronic pain conditions [30]. While this study was designed to collect data pertaining to the different clinical phenotypes using the UPOINT system and conduct exploratory subgroup analyses, these analyses were not feasible due to early study termination and the reduced sample size. Future studies of adequate sample size should further explore treatment response according to clinical phenotypes.

Conclusions

In patients with moderate to severe chronic bladder pain from IC/BPS, fulranumab at the single dose (9 mg) tested failed to show analgesic activity as compared with placebo, although the study findings are limited by early study termination and imbalance in the baseline characteristics of the study population. IC/BPS remains a difficult medical condition in need of satisfactory therapies.

Abbreviations

ANOVA: Analysis of variance; FDA: Food and Drug Administration; GRA: Global response assessment; IC/BPS: Interstitial cystitis/bladder pain syndrome; ICSI: Interstitial cystitis symptom index; ITT: Intent-to-treat; NGF: Nerve growth factor; NRS: Numerical rating scale; PPRC: Patient Perception of Bladder Condition; PPS: Pentosan polysulfate sodium; PUF: Pelvic Pain and Urgency/Frequency Questionnaire; SC: Subcutaneously; SD: Standard deviation

Acknowledgments

Writing support was provided by Sandra Norris, Pharm.D. of the Norris Communications Group, LLC and funded by Janssen Research & Development, LLC. The authors thank Luqiang Wang, PhD, contract statistician of Janssen, for review of and statistical contributions to the manuscript. Ellen Baum, Ph.D. (of Janssen Research & Development, LLC) provided additional editorial assistance.

The authors also thank the study participants of this study, without whom the study would never have been accomplished, and the investigators for their participation in the study (i.e., randomized patients): ONTARIO CANADA: Jack Barkin, MD; Joseph Zadora, MD; UNITED STATES: California: Edward Davis, MD; Bruce Khan, MD; Marianne Rochester, MD; Florida: Marc Gittelman, MD; Louisiana: Samuel Alexander, MD; Neil Baum, MD; Kevin Cline, MD; New Jersey: Eric Margolis, MD; New York: Evan Goldfischer, MD; and North Carolina Robert Lamar Parker, MD.

Funding

This study was funded by Janssen Research & Development, LLC.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HW and JT were involved in study design and KMK and JT were involved in data review and analysis for the study. LJR served as the Medical Monitor for the study and reviewed data and analyses for the study. SW was involved in study design, data review and analysis, and performed the statistical analysis. All authors contributed to writing drafts of the article. All authors approved the final version of the article, including the authorship list.

Competing interests

Dr. Hao Wang was an employee of Janssen Research & Development, LLC, in Raritan/Titusville, NJ, USA during the conduct of this study; Dr. Wang currently declares no other conflicts of interest. Drs. Kathleen Kelly, Steven Wang, and John Thipphawong are employees of Janssen Research & Development, LLC, in Raritan/Titusville, NJ, USA. Dr. Lucille Russell was an employee of Janssen Research & Development, LLC, in Raritan/Titusville, NJ, USA at the time this study was conducted and this manuscript was written and submitted for publication.

Consent for publication

This manuscript does not include details, images, or videos relating to individual participants, therefore there was no need to obtain written informed consent for publication from the participants.

Ethics approval and consent to participate

The study protocol and its amendments were approved by an Independent Review Board or Research Ethics Board at the following sites: Canada – The Male Health Centre, Toronto; and, the Male/Female Health and Research Centre, Barrie, Ontario; United States – California: Citrus Valley Medical Research, Glendora; San Diego: Uro-Research, San Diego; Scripps Clinic, San Diego; Florida: South Florida Medical Research, Aventura; Louisiana: Clinical Trials Management, LLC, Metairie; Best Clinical Trials, New Orleans; Regional Urology, Shreveport; New Jersey: Urology Center of Englewood, Englewood; New York: Hudson Valley Research, Poughkeepsie; North Carolina: Lyndhurst Clinical Research, Winston Salem.

Author details

1Office of Translational Research, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA. 2Janssen Research & Development, LLC, Raritan/Titusville, NJ, USA.

Received: 10 November 2015 Accepted: 14 December 2016

Published online: 05 January 2017

References

1. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA Guideline Amendment. J Urol. 2015;193(5):1545–53.
2. Clemens QJ, Link CL, Eggers PW, Kusek JW, Nyberg Jr LM, McKinlay JB, BACH Survey Investigators. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol. 2007;177(4):1390–4.
3. Rothrock N, Lutgendorf SK, Kieder KJ. Coping strategies in patients with interstitial cystitis: relationships with quality of life and depression. J Urol. 2003;169(1):233–6.
4. Warren JW, Howard FM, Cross RK, Good JL, Weisstein MM, Wesselmann U, Langenberg P, Greenberg P, Clauw DJ. Antecedent nonbladder syndromes in case-control study of interstitial cystitis/painful bladder syndrome. Urology. 2009;73(1):52–7.
5. Wesselmann U. Interstitial cystitis: a chronic visceral pain syndrome. Urology. 2001;57(6 Suppl 1):32–9.
6. Chong M, Hester J. Pharmacotherapy for neuropathic pain with special reference to urogentinal pain. In: Baronowski A, Abrams P, Fall M, editors. Urogental pain in clinical practice. New York Informa Healthcare USA, Inc; 2007. p. 427.
7. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91.

8. Ochodnicky P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41.

9. Fujita M, Kasai E, Omachi S, Sakaguchi G, Shinohara S. A novel method for assessing bladder-related pain reveals the involvement of nerve growth factor in pain associated with cyclophosphamide-induced chronic cystitis in mice. Eur J Pain. 2015. doi: 10.1002/ejp.693. [Epub ahead of print].

10. Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23 Suppl 1:158–17.

11. Wang H, Romano G, Frustaci ME, Bohidar N, Ma H, Sanga P, Ness S, Russell LJ, Fedgchin M, Kelly KM, Thippahwong J. Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial. Neurology. 2014;83(7):528–37.

12. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg WT, Mazloomdoost D, Amadera JE. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Pain Physician. 2014;17(1):45–60.

13. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Schofield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(S5):1716–21.

14. Nickel JC, Atkinson G, Krieger JN, Mills IW, Pontari M, Shoskes DA, Crook TJ. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80(S1):110–10.

15. Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, Thipphawong J. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain. 2013;154(10):1910–9.

16. Mayorga A, Wang S, Wang S, Kelly K, Thippahwong J. Double-blind, randomized study to evaluate efficacy and safety of fulranumab in patients with moderate to severe, chronic knee pain from osteoarthritis: interim analysis results (abstract 375). J Pain. 2013;14(4):S69.

17. Sanga P, Karcher K, Wang S, Kelly K, Ch C, Thippahwong J. Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate to severe, chronic low back pain (abstract 310). J Pain. 2011;12(4):53.

18. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23 Suppl 1:518–21.

19. O’Leary MP, Sant GR, Fowler Jr FJ, Whitmore JE, Kotlarz-Kool J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(Suppl 5A):58–63.

20. Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the Oteany-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001;57(6 Suppl 1):62–6.

21. Dworkin RH, Krug CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227–41.

22. Parson J, Sanger K, Ahmed K, Masood S, Dasgupta P, Khan MS. Painful bladder syndrome/interstitial cystitis: aetiology, evaluation and management. Arch Ital Urol Androl. 2014;86(2):126–31.

23. Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol. 2014;175:30–7.

24. Dyer AJ, Twiss CO. Painful bladder syndrome: an update and review of current management strategies. Curr Urol Rep. 2014;15(2):384.

25. Pfizer. Tanezumab Arthritis Advisory Briefing Document, 8 February 2012. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ UCM295205.pdf. Accessed 4 November 2015.

26. Nickel JC, Tripp DA, International Interstitial Cystitis Study Group. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. J Urol. 2015;193(1):138–44.

27. Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, Wyndaele J. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.

28. Sant GR, Propert KI, Hanno PM, Burks D, Cullin D, Dickson AC, Hardy C, Landis JR, Mayer R, Madigan M, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kuske JV, Nyberg LW, Interstitial Cystitis Clinical Trials Group. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810–5.

29. Parsons CL, Benson C, Childs S, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentanacypolyne. J Urol. 1993;150(3):845–8.

30. Nickel JC, Forrest J, Barkin J, Payne C, Mosbaugh P. Safety and efficacy of up to 900 mg/day polysulfate sodium (Elmiron) in patients with interstitial cystitis. Urology. 2001;57(6 Suppl 1):122–3.

31. Nickel JC, Irvine-Bird K, Jianbo L, Shoskes DA. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–9.